Clinical management of cavernous malformations
KD Flemming - Current cardiology reports, 2017 - Springer
KD Flemming
Current cardiology reports, 2017•SpringerAbstract Purpose of Review This study aims to review the current epidemiology and clinical
management of patients with cavernous malformations (CM). Recent Findings Hemorrhage
is the most feared complication and leads to morbidity in patients with CM. Multiple studies
including three meta-analyses have provided useful estimates of hemorrhage risk, but have
failed to identify a modifiable risk factor for prevention of cavernous malformation related
hemorrhage. In treating the CM itself, surgical risk is weighed against the natural history …
management of patients with cavernous malformations (CM). Recent Findings Hemorrhage
is the most feared complication and leads to morbidity in patients with CM. Multiple studies
including three meta-analyses have provided useful estimates of hemorrhage risk, but have
failed to identify a modifiable risk factor for prevention of cavernous malformation related
hemorrhage. In treating the CM itself, surgical risk is weighed against the natural history …
Purpose of Review
This study aims to review the current epidemiology and clinical management of patients with cavernous malformations (CM).
Recent Findings
Hemorrhage is the most feared complication and leads to morbidity in patients with CM. Multiple studies including three meta-analyses have provided useful estimates of hemorrhage risk, but have failed to identify a modifiable risk factor for prevention of cavernous malformation related hemorrhage. In treating the CM itself, surgical risk is weighed against the natural history. However, accumulating knowledge regarding the roles of CCM 1, 2, and 3 genes has led to the discovery of potential therapeutic targets.
Summary
The risk of future hemorrhage in patients with CM is highest in those who have had previously clinical hemorrhages. Estimated risks are helpful in counseling patients and comparing to the risk of surgery. Future clinical trials of candidate medications are likely to target those patients with prior clinical hemorrhage in whom the surgical risk is deemed high.
Springer